The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
July 11th 2025
Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.
Building a Sustainable Pharmacogenomics Program: A Pharmacist’s Perspective at Ochsner Health
July 7th 2025Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.
Read More
Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations
July 7th 2025Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Read More
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
Published: July 2nd 2025 | Updated: July 2nd 2025The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
Read More
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
Read More
ASCO 2025: How AI-Powered Tools Are Reshaping Oncology Data Capture and Clinical Decision-Making
June 30th 2025Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.
Read More
Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP
June 27th 2025Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.
Read More
Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.
Read More
Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research
June 24th 2025Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.
Watch
Psychedelic Group Therapy Expands From Cancer Care to Treat PTSD in Active Duty Military
June 23rd 2025Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military posttraumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.
Watch
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.
Read More